Emerging Therapeutic Strategies in the Management of Anemia in Patients with CKD Evaluation (ID: i747b)

Question Title

* 1. How committed are you to making changes in your practice based on your participation in this activity?

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

Question Title

* 2. After participating in today’s activity, I am now able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Describe the prevalence of and burden associated with anemia in patients with CKD, particularly those who are hyporesponsive to ESA therapy	Describe the prevalence of and burden associated with anemia in patients with CKD, particularly those who are hyporesponsive to ESA therapy Strongly agree	Describe the prevalence of and burden associated with anemia in patients with CKD, particularly those who are hyporesponsive to ESA therapy Agree	Describe the prevalence of and burden associated with anemia in patients with CKD, particularly those who are hyporesponsive to ESA therapy Neutral	Describe the prevalence of and burden associated with anemia in patients with CKD, particularly those who are hyporesponsive to ESA therapy Disagree	Describe the prevalence of and burden associated with anemia in patients with CKD, particularly those who are hyporesponsive to ESA therapy Strongly disagree
Discuss the pathogenic mechanisms involved in anemia associated with CKD, including the roles of inflammation, hepcidin, and the HIF pathway	Discuss the pathogenic mechanisms involved in anemia associated with CKD, including the roles of inflammation, hepcidin, and the HIF pathway Strongly agree	Discuss the pathogenic mechanisms involved in anemia associated with CKD, including the roles of inflammation, hepcidin, and the HIF pathway Agree	Discuss the pathogenic mechanisms involved in anemia associated with CKD, including the roles of inflammation, hepcidin, and the HIF pathway Neutral	Discuss the pathogenic mechanisms involved in anemia associated with CKD, including the roles of inflammation, hepcidin, and the HIF pathway Disagree	Discuss the pathogenic mechanisms involved in anemia associated with CKD, including the roles of inflammation, hepcidin, and the HIF pathway Strongly disagree
Explain the clinical utility of measuring hepcidin levels in patients with anemia and CKD	Explain the clinical utility of measuring hepcidin levels in patients with anemia and CKD Strongly agree	Explain the clinical utility of measuring hepcidin levels in patients with anemia and CKD Agree	Explain the clinical utility of measuring hepcidin levels in patients with anemia and CKD Neutral	Explain the clinical utility of measuring hepcidin levels in patients with anemia and CKD Disagree	Explain the clinical utility of measuring hepcidin levels in patients with anemia and CKD Strongly disagree
Review outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD	Review outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD Strongly agree	Review outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD Agree	Review outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD Neutral	Review outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD Disagree	Review outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD Strongly disagree

Question Title

* 3. The content presented:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Enhanced my current knowledge base	Enhanced my current knowledge base Strongly agree	Enhanced my current knowledge base Agree	Enhanced my current knowledge base Neutral	Enhanced my current knowledge base Disagree	Enhanced my current knowledge base Strongly disagree
Addressed my most pressing questions	Addressed my most pressing questions Strongly agree	Addressed my most pressing questions Agree	Addressed my most pressing questions Neutral	Addressed my most pressing questions Disagree	Addressed my most pressing questions Strongly disagree
Promoted improvements or quality in health care	Promoted improvements or quality in health care Strongly agree	Promoted improvements or quality in health care Agree	Promoted improvements or quality in health care Neutral	Promoted improvements or quality in health care Disagree	Promoted improvements or quality in health care Strongly disagree
Was scientifically rigorous and evidence based	Was scientifically rigorous and evidence based Strongly agree	Was scientifically rigorous and evidence based Agree	Was scientifically rigorous and evidence based Neutral	Was scientifically rigorous and evidence based Disagree	Was scientifically rigorous and evidence based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Question Title

* 4. How many CKD patients with anemia do you manage in your practice?

Question Title

* 5. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 6. What barriers do you see to making changes in your practice?

Question Title

* 7. If you indicated that you perceived commercial bias or influence, please describe: